Crossmark

Author Correction: Safety and feasibility of 4-1BB co-stimulated CD19-specific CAR-NK cell therapy in refractory/relapsed large B cell lymphoma: a phase 1 trial

Crossref DOI link: https://doi.org/10.1038/s43018-025-01026-w

Published Online: 2025-07-03

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Lei, Wen

Liu, Hui https://orcid.org/0000-0003-1452-5062
Deng, Wenhai https://orcid.org/0000-0003-3270-5980
Chen, Wei https://orcid.org/0000-0002-8375-518X
Liang, Yun

Gao, Wenxia

Yuan, Xianggui

Guo, Shanshan

Li, Ping

Wang, Jinyong

Tong, Xiangmin https://orcid.org/0000-0002-4175-0321
Sun, Yi Eve https://orcid.org/0000-0002-1272-3295
Liang, Aibin https://orcid.org/0000-0002-8978-1987
Qian, Wenbin https://orcid.org/0000-0002-9817-6674
License Information

Text and Data Mining valid from 2025-07-03

Version of Record valid from 2025-07-03
More Information

Article History

First Online: 3 July 2025